#Switzerland #ADC Therapeutics #ZYNLONTA #Lausanne

ADC Therapeutics Unveils Employee Inducement Grant

ADC Therapeutics SA (NYSE: ADCT), a frontrunner in the field of antibody drug conjugates (ADCs), announced a significant employee inducement grant on November 2, 2026. This initiative is part of the company’s continuous effort to attract top talent and foster excellence within its team.

The company allocated 17,000 options for common shares to a new employee, signaling its commitment to incentivizing performance and ensuring the new hire feels valued from the onset. This grant was given under the auspices of the Company’s Inducement Plan, specifically designed to motivate employees to perform at their best and contribute meaningfully to the company’s objectives.

The granting of stock options serves multiple purposes: it aligns the interests of employees with those of shareholders, promotes retention, and enhances job satisfaction. The options offered in this grant will vest at a rate of 25% on the first anniversary of the grant date, and then 1/48th of the total each month thereafter. This structure means the employee will fully benefit from the grant after four years, which encourages longevity within the company.

This announcement is timely as ADC Therapeutics continues to innovate within the biotechnology landscape. The firm is at the forefront of developing groundbreaking therapeutic solutions, including its product ZYNLONTA® (loncastuximab tesirine-lpyl), designed specifically for patients battling relapsed or refractory diffuse large B-cell lymphoma.

Headquartered in Lausanne, Switzerland, the company has demonstrated a keen focus on clinical and manufacturing innovation, which is integral to its strategic operations. The CEO and the executive team remain optimistic about the growth trajectory of ADC Therapeutics, particularly as they expand their portfolio and reach in international markets.

Additionally, ADC Therapeutics has been proactive in adapting to market demands and investor expectations. The recent inducement grant reflects a practice applauded by market analysts and investors alike, as it underscores the company’s focus on creating a high-performing culture supported by a robust reward system.

The board's Compensation Committee approved this grant, adhering to the employment inducement exemption as outlined in the NYSE’s Listed Company Manual. By taking such strategic steps, ADC Therapeutics is positioning itself not only as an industry pioneer but also as an attractive workplace for prospective talents in the biotech field.

As ADC Therapeutics continues to pave the way in the development of antibody drug conjugates, this employee inducement grant is a clear indication of its commitment to cultivating a motivated workforce that can drive the company's mission forward. The firm encourages its employees to reach new heights while also laying the groundwork for sustained innovation that will ultimately enhance patient treatment experiences.

In summary, ADC Therapeutics’ recent employee inducement grant is a testament to its strategic vision of aligning employee rewards with company success. As the biotech firm continues to carve out its legacy within the industry, the importance of nurturing talent through initiatives like this will remain paramount for achieving long-term goals and fostering a culture of achievement and excellence.